Third-line life-prolonging drugs (LPDs) might not be appropriate for all metastatic castration-resistant prostate cancer patients. We developed a prognostic model and identified a high-risk subgroup in which no meaningful benefit from third-line LPDs is derived in clinical practice

Aben, Katja K. H.

Bergman, Andries M.

Coenen, Jules L. L. M.

de Vos, Aad

Gerritsen, Winald R.

Kuppen, Malou C. P.

Mehra, Niven

Notohardjo, Jessica C. L.

Somford, Diederik M.

Uyl-de Groot, Carin A.

van den Bergh, Alphons C. M.

van den Eertwegh, Alfons J. M.

van Moorselaar, Reindert J. A.

van Oort, Inge M.

Vervenne, Walter L.

Westgeest, Hans M.

English

Third-line life-prolonging drugs (LPDs) might not be appropriate for all metastatic castration-resistant prostate cancer patients. We developed a prognostic model and identified a high-risk subgroup in which no meaningful benefit from third-line LPDs is derived in clinical practice.</p

Notohardjo, Jessica C.L.

Kuppen, Malou C.P.

van Moorselaar, Reindert J.A.

Coenen, Jules L.L.M.

de Vos, Aad I.

van den Bergh, Alphons C.M.

Aben, Katja K.H.

van den Eertwegh, Alfons J.M.

EUR Research Repository

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population:Results from the Dutch Castration-resistant Prostate Cancer Registry

University of Groningen

Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 31, 2017. Outcome measurements and statistical analysis: Association of potential risk factors with OS was tested by Cox proportional hazard models after multiple imputation of missing baseline characteristics. A predictive score was computed from the regression coefficient and used to classify patients into risk groups. Results and limitations: Of 1011 mCRPC patients progressive on second-line LPD, 602 (60%) received third-line LPD. Patients receiving third-line LPD had a more favorable prognostic profile at baseline and longer median OS than patients with best supportive</p

Dissertations of the University of Groningen

Background: Evidence concerning third-line life-prolonging drugs (LPDs) in the treat-ment of metastatic castration-resistant prostate cancer (mCRPC) patients is incomplete. Objective: To evaluate third-line LPD outcomes in a real-world cohort of mCRPC patients, identify variables associated with overall survival (OS), and establish a prog-nostic model. Design, setting, and participants: Patients with mCRPC who were progressive on second-line LPD before July 1, 2017 were retrospectively identified from the Dutch Castration-resistant Prostate Cancer Registry (CAPRI) and followed until December 31, 2017. Outcome measurements and statistical analysis: Association of potential risk factors with OS was tested by Cox proportional hazard models after multiple imputation of missing baseline characteristics. A predictive score was computed from the regression coefficient and used to classify patients into risk groups. Results and limitations: Of 1011 mCRPC patients progressive on second-line LPD, 602 (60%) received third-line LPD. Patients receiving third-line LPD had a more favorable prognostic profile at baseline and longer median OS than patients with best supportiv

NARCIS 

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry

Proceedings - University of Groningen

ARTS repository - University of Groningen

https://pure.rug.nl/ws/files/200109051/1_s2.0_S2405456920300973_main.pdf

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population:Results from the Dutch Castration-resistant Prostate Cancer Registry

Abstract

Similar works

Full text

Available Versions

EUR Research Repository

University of Groningen

University of Groningen

Dissertations of the University of Groningen

NARCIS

Proceedings - University of Groningen

ARTS repository - University of Groningen

Dissertations of the University of Groningen

NARCIS

Proceedings - University of Groningen